Health
New gene therapy could treat dominant optic atrophy – Drug Target Review
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Posted: 27 November 2020 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have found that an OPA1-targeted gene therapy can treat dominant optic atrophy in pre-clinical trials.
Scientists have developed a new gene therapy approach that they say offers promise for one day treating an eye disease that leads to a progressive loss of vision and affects thousands of people across the globe. The study was led by researchers at Trinity College Dublin, Ireland.
A fluorescent microscope…
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News11 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Business14 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025